Kimberly-Clark to Acquire Kenvue in $48.7 Billion Deal
Kimberly-Clark (KMB) announces acquisition of Kenvue (KVUE) for $48.7 billion, creating a global health and wellness powerhouse with 10 billion-dollar brands serving consumers worldwide.
/ 1676 items
#XY↓
Alvotech's Biosimilar Drug Faces FDA Setback Due to Manufacturing Issues
Alvotech receives FDA complete response letter for AVT05 biosimilar to Simponi, citing manufacturing facility deficiencies. Company revises 2025 revenue outlook downward.
Pfizer Sues Metsera and Novo Nordisk Over Breach of Merger Agreement
Pfizer files lawsuit against Metsera, its board, and Novo Nordisk for breaching a merger agreement, claiming illegal interference and regulatory risks in Novo Nordisk’s proposal.
Ironwood Rises as AbbVie’s Linzess Sales Beat Expectations
Ironwood shares climb after AbbVie reports strong Q3 Linzess sales of $315M, surpassing estimates and boosting investor confidence.
Travere Therapeutics Surges After Swinging to Q3 Profit and Crushing Analyst Estimates
Travere Therapeutics shares jumped 15% after reporting a strong Q3 profit of $25.7M, driven by surging FILSPARI sales and better-than-expected earnings. Citi raised its price target to $48, citing optimism for FDA approval in early 2026.
FDA’s New Fast-Track Plan for Custom Gene Editing Could Transform Rare Disease Treatments
The FDA is unveiling a faster approval pathway for custom gene-editing therapies, aiming to spark major investment and accelerate cures for rare diseases through Crispr-based innovations.